Mitchell Kapoor Recommends Buy for Neurogene Due to Strong NGN-401 Low-Dose Safety and Potential Upside
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
Promising Outlook for Neurogene’s Low-Dose NGN-401 Program in Rett Syndrome
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
BioSpace1d
Neurogene Drops Batten Gene Therapy Program
Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
biopharma-reporter1d
Serious adverse event causes problems for Neurogene’s Rett gene therapy
A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...
Le Lézard1d
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") .   Such investors are advised to contact Danielle Peyton at [email protected] or ...
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...
pharmaphorum2d
Neurogene falls again on Rett gene therapy side effects
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...
Neurogene stock plunges 36% on NGN-401 study update
Neurogene (NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on ...
MarketWatch2d
Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...
BioWorld2d
Gender bias leaves women at risk in cardiology treatment guidelines
Neurogene slides on Rett syndrome gene therapy safety concern Neurogene Inc.’s stock sank 43.5% in early trading Nov. 18 on news that its phase I/II gene therapy NGN-401 resulted in a serious adverse ...
BioWorld2d
Neurogene slides on Rett syndrome gene therapy safety concern
Neurogene Inc.’s stock sank 43% on news that its phase I/II gene therapy, NGN-401, resulted in a serious adverse event in a pediatric Rett syndrome patient receiving the highest dose.